However, only modest therapeutic effects have been observed in all these malignancies since mTOR inhibitors may have more of a cytostatic rather than a cytotoxic effect, with a benefit mainly in terms of disease stabilization and progression free survival (PFS) improvement rather than tumor shrinkage. Here, MTOR is linked to neoplasm.